ライフサイエンスコーパス: protein kinase C-beta

1 hondrial function and longevity, by reducing protein kinase C-beta.

2 is increased after PMA-evoked activation of protein kinase C-beta.

3 ding those for annexin VI, interleukin-4 and protein kinase C-beta.

4 between PKCI-1 and the regulatory domain of protein kinase C-beta.

5 able transfection of expression plasmids for protein kinases C beta 1 (PKC beta 1) or PKC beta 2 into

6 se C (PLC), phospholipase D (PLD), Ca2+, and protein kinase C beta 2 (PKCbeta2) inhibited OZ-induced

7 lted in a preferential decrease in epidermal protein kinase C-beta 2 (PKC-beta 2) compared with PKC-a

8 We further identify a BAFF-specific protein kinase C beta-Akt signaling axis, which provides

9 duced phosphorylation of the kinases Lyn and protein kinase C-beta and MAPKs MKK-3/6 and p38MAPK or t

10 tagged lipid-binding proteins such as epsin, protein kinase C-beta, and synaptobrevin.

11 x, including synaptotagmin I, cAMP-dependent protein kinase C beta, apolipoprotein E, protein phospha

12 A specific inhibitor of protein kinase C-beta blocked the substrate-mediated inc

13 a mechanism dependent on SNARE proteins and protein kinase C-beta but independent of dopamine D(2) r

14 binding to C2 domains of synaptotagmin I and protein kinase C-beta by nuclear magnetic resonance spec

15 Among the protein knase C isoforms tested, protein kinase C beta, delta, and epsilon were most effe

16 Haploinsufficiency or complete deficiency of protein kinase C beta, Fyn, CD22, Galphaq, or Galpha11 h

17 the Src-family protein tyrosine kinase Lyn, protein kinase C beta I/II (PKCbetaI/II), and Erk2-speci

18 Elevated expression of protein kinase C beta II (PKC beta II) is an early promo

19 the unphosphorylated turn motif (Thr(641) in protein kinase C beta II), one of three priming sites ph

20 tion of the interaction with Hsp70 slows the protein kinase C beta II-mediated recovery of cells from

21 irect binding of this class of activators to protein kinase C beta II.

22 Using homozygous null mice for the protein kinase C beta-isoform gene (PKCbeta null), PKCbe

23 trast, treatment with D-alpha-tocopherol and protein kinase-C beta-isoform inhibition (LY333531) prev

24 ds induced by diabetes mellitus can activate protein kinase C-beta isoforms and selectively inhibit i

25 Abnormal activation of protein kinase C-beta isoforms in the diabetic state has

26 ling, but GC cells signaled less through the protein kinase C-beta-NF-kappaB pathway and produced str

27 Using the HL-60 cell variant deficient in protein kinase C-beta (PKC-beta) and several stable PKC-

28 The role of protein kinase C-beta (PKC-beta) in apoptosis induced by

29 AI-1 induction was suppressed by a selective protein kinase C-beta (PKC-beta) inhibitor.

30 Protein kinase C-beta (PKC-beta) is immediately downstre

31 We have previously shown that protein kinase C-beta (PKC-beta) is required for activat

32 osolic phospholipase A2-alpha (cPLA2-alpha), protein kinase C-beta (PKC-beta), and synaptotagmin-IA (

33 B cells from protein kinase C-beta (PKC-beta)-deficient mice failed t

34 We have identified protein kinase C beta (PKCbeta) as a critical mediator o

35 we identify the calcium-regulated classical protein kinase C beta (PKCbeta) as a repressor of myogen

36 the recommended dose of enzastaurin, an oral protein kinase C beta (PKCbeta) inhibitor, for phase II

37 Protein kinase C beta (PKCbeta) participates in antigen-

38 Protein kinase C beta (PKCbeta) regulated MIF-induced IL

39 by counteracting the negative influences of protein kinase C beta (PKCbeta) via dephosphorylation an

40 Protein kinase C beta (PKCbeta) was identified by gene-e

41 Using mice deficient for protein kinase C beta (PKCbeta) we show an essential rol

42 One key mediator of BCR signaling is protein kinase C beta (PKCbeta), which regulates the act

43 d that combined small-molecule inhibition of protein kinase C-beta (PKCbeta) and glycogen synthase ki

44 l insulin signaling, through the activity of protein kinase C-beta (PKCbeta) and nuclear factor kappa

45 While targeted disruption of the protein kinase C-beta (PKCbeta) gene in mice results in

46 ogen-independent effects, such as inhibiting protein kinase C beta (PKCbeta1).